Fidel Valea appointed to leadership roles in gynecologic oncology at Northwell Health

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Fidel A. Valea was appointed system chief of gynecologic oncology at Northwell Health and director of gynecologic oncology at the Northwell Health Cancer Institute. In these roles, he will see patients in New Hyde Park and Manhattan.

Valea is joining Northwell from the Virginia Tech Carilion School of Medicine, where he was chair of obstetrics and gynecology for five years. Prior to that, Valea held several leadership roles during his 12-year tenure at Duke University School of Medicine, including vice chair of education, residency program director in obstetrics and gynecology, fellowship director in gynecologic oncology, and tenured professor. 

In his role as system chief of gynecologic oncology at Northwell Health, Valea will direct gynecologic oncology programs across the health system. Key areas of responsibility include: advancing a patient-centered approach to care, overseeing performance improvement and quality assurance studies, enhancing operational efficiencies, developing educational and academic offerings for the fellowship program and other clinical staff, and expanding gynecologic oncology research efforts.

As director of gynecologic oncology at the Northwell Health Cancer Institute, Valea will direct the development of the gynecologic oncology program throughout the health system’s central region, working with Northwell’s Divi

sion of Gynecologic Oncology.

Valea recently completed his tenure as director of Gynecologic Oncology for the American Board of Obstetrics and Gynecology and served on its board. He is one of four editors of Comprehensive Gynecology. Valea’s research interests are in pre-invasive disease of the cervix, minimally invasive surgery, and evidence-based perioperative care. 

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login